Andrew Geall, Ph.D.
Co-Founder and Chief Development Officer, Replicate Bioscience
Dr. Andrew Geall has over 20 years of experience developing drug delivery systems as a pioneer in mRNA vaccines and nucleic acid delivery. He currently serves as the chief development officer at Replicate Bioscience, which he cofounded. Prior to Replicate, Andrew was chief scientific officer at Precision NanoSystems Inc. He has also served as vice president of formulations, analytics and chemistry at Avidity Biosciences, RNA Vaccine Platform Leader at Novartis Vaccines, and Senior Fellow at Novartis Pharmaceuticals AG.
Andrew holds a pharmacy degree from the University of Bath in the United Kingdom and completed pre-registration training in the aseptic dispensing unit at St Helens and Knowsley Trust Hospitals. He obtained a Ph.D. at the University of Bath in non-viral gene delivery.
Meet the rest of our
see all team members
Jodie Morrison
Chief Executive Office and Director, Q32 Bio Inc.
Fred Fiedorek, M.D.
Chief Medical Officer
Issi Rozen
Venture Partner, GV
Sekar Kathiresan, M.D.
Co-Founder, Chief Executive Officer and Board Member
Lonnel Coats
Chief Executive Officer and Director, Lexicon Pharmaceuticals
Joan Nickerson
Chief Administrative Officer
Barry Ticho, M.D., Ph.D.
Chief Medical Officer, Stoke Therapeutics
Nia Tatsis, Ph.D.
Executive Vice President and Chief Regulatory and Quality Officer, Vertex Pharmaceuticals
Sheila Mikhail, J.D.
Co-Founder and Former Chief Executive Officer, AskBio; Co-Founder and Chief Executive Officer, Jurata Thin Film
J. Keith Joung, M.D., Ph.D.
Robert B. Colvin, M.D. Endowed Chair in Pathology and Pathologist, Massachusetts General Hospital; Professor of Pathology, Harvard Medical School
Anthony Philippakis, M.D., Ph.D.
Chief Data Officer, Broad Institute of MIT and Harvard
Kiran Musunuru, M.D., Ph.D.
Professor of Cardiovascular Medicine and Genetics, Perelman School of Medicine at the University of Pennsylvania
Bo Cumbo
President and Chief Executive Officer, Solid Biosciences
Michael MacLean
Chief Financial Officer and Chief Business Officer, Avidity Biosciences
Krishna Yeshwant, M.D.
Managing Partner, GV
Yasser (Yas) El-Gamal, J.D.
Senior Vice President, Legal Affairs and Chief Intellectual Property Counsel
Daniel J. Rader, M.D.
Chair, Department of Genetics, University of Pennsylvania
Andrew Ashe, J.D.
President, Chief Operating Officer and General Counsel
Troy Lister, Ph.D.
Chief Scientific Officer
Burt Adelman, M.D.
Chairman of the Board; former EVP and Chief Medical Officer, Dyax
Allison Dorval
Chief Financial Officer
Eugene Braunwald, M.D.
Distinguished Hersey Professor of Medicine at Harvard Medical School
Leslie Stolz, Ph.D.
Senior Vice President, Regulatory Affairs
